Low Testosterone and Cardiovascular Disease: Risk Marker, Mediator, or Both?
Low testosterone is consistently associated with adverse cardiovascular outcomes, but whether it is a cause of vascular disease or a marker of underlying metabolic and inflammatory dysfunction remains unresolved. This review examines the epidemiology, vascular mechanisms, hypertension and atherosclerosis data, TRAVERSE findings, and the cardiovascular implications of TRT-induced erythrocytosis.
Key point 1: Low endogenous testosterone is consistently associated with cardiovascular risk, but association does not establish causation. Observational studies link lower testosterone with cardiovascular mortality, hypertension, and greater atherosclerotic burden, while other large cohorts report weaker or null associations after adjustment. The key unresolved question is whether testosterone is a causal mediator of vascular disease or a marker of aging, obesity, inflammation, and poor metabolic health.
Key point 2: There are biologically plausible pathways connecting testosterone deficiency with vascular dysfunction. Testosterone influences endothelial nitric oxide production, inflammatory signaling, visceral adiposity, insulin sensitivity, and vascular tone. These mechanisms could help explain associations with hypertension and atherosclerosis, although human and animal findings are not always consistent and interventional evidence has not established that testosterone replacement slows plaque progression.
Key point 3: TRT presents a different cardiovascular question from low endogenous testosterone. TRAVERSE found testosterone therapy non-inferior to placebo for major adverse cardiovascular events in men with confirmed hypogonadism and elevated cardiovascular risk, but secondary safety signals remained. The article particularly emphasizes TRT-induced erythrocytosis, which can increase blood viscosity, vascular resistance, and arterial wall stress, illustrating why correcting low testosterone is not synonymous with eliminating cardiovascular risk.
First published in Naturopathic Doctor News & Review, October 2026.
Read the full article, with references, at Naturopathic Doctor News & Review